Development of an antimicrobial cement using human defensins-like antimicrobial peptides by Feng, Siqiao
  
 
 
 
Development of an Antimicrobial Hydroxyapatite Cement 
Using  Human Defensins-Like Antimicrobial Peptides 
 
 
By 
Siqiao Feng 
A thesis submitted to the School of Metallurgy and 
Materials of University of Birmingham for the degree  
of 
 
MRes 
 
 
School of Metallurgy and Materials 
The University of Birmingham 
 
June 2014  
 
 
 
 
 
 
 
 
 
University of Birmingham Research Archive 
 
e-theses repository 
 
 
This unpublished thesis/dissertation is copyright of the author and/or third 
parties. The intellectual property rights of the author or third parties in respect 
of this work are as defined by The Copyright Designs and Patents Act 1988 or 
as modified by any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission 
of the copyright holder.  
 
 
 
Siqiao Feng 
 
I 
 
ABSTRACT 
 
Bone cements are used in orthopaedics mainly as fixation devices in hip joints. One of 
the most important bone cements is Hydroxyapatite (HA) cement. It is widely used 
due to its advantages that include biocompatibility, bioactivity and low setting 
temperatures. HA cements can absorb bacteria leading to infection during surgery. In 
order to solve this problem, antimicrobial hydroxyapatite bone cements need to be 
developed. 
Antimicrobial peptides (APs) are low molecular weight natural compounds. APs with 
a broad spectrum of antimicrobial activity act as the first line of defence against 
bacterial invasion in almost all forms of life. Human defensins represent one type of 
the most important antimicrobial peptides. The main advantage of human defensins is 
that they can avoid bacterial resistance which is a significant problem when 
antibiotics are used. However, the sequence of human defensins is very long and 
therefore very difficult to synthesise high purity antimicrobial peptides. If synthetic 
defensins with a short peptide sequence can still exhibit antimicrobial properties, 
synthetic defensins could be used. This work focuses on isolating fragments from the 
antimicrobial core of human defensins that can have significant antimicrobial 
properties and incorporating them in HA cements in order to make antimicrobial bone 
cements.  
Four peptide sequences were selected from α- and β- human defensins. One peptide 
sequence with the best antimicrobial property was selected to incorporate with HA 
cements. Mass spectrometry and HPLC were used to identify the molar mass and 
purity of the peptide, respectively. The antimicrobial properties were studied by 
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measuring the minimum inhibitory concentration (MIC) of the peptides. The pH, 
antimicrobial properties, peptide release and mechanical properties (compressive 
strength) of bone cements were measured against different concentrations of the 
peptide.  
All four fragments from the antimicrobial core of human defensins showed 
antimicrobial activity against E.coli, S.aureus and P.aeruginosa. Peptide AP4 with the 
shortest sequence (9-amino acid) had the best purity and the lowest MIC. In this 
research all pH values of HA cements with different concentration of peptides were at 
7 indicating that all cement pastes underwent phase transition to HA. With the 
concentration of peptide increasing, the amount of peptide released was increased. For 
each concentration, during the first 0.5 hour, the release rate was higher than between 
0.5 hour and 3 hours. After 48 hours, the peptide release concentration reached a 
plateau with no significant change. When the concentration of AP4 in the cement was 
increased, the compressive strength was decreased. The 24 hours compressive 
strength of each concentration was lower than 48 hours. The antimicrobial property of 
HA cements was increased with increasing the concentration of AP4. However, HA 
cements with highest concentration of 8 wt% of antimicrobial peptide could not 
completely eliminate bacteria. The antimicrobial property between 24 hours and 48 
hours was not very different. An attempt to calculate the surface concentration of the 
antimicrobial peptide assuming homogeneous distribution of the peptide in the HA 
cement lead to the conclusion that the concentration of peptide on the surface was 
lower than the MIC of AP4. It can be concluded that the AP4 was not a very good 
choice of antimicrobial peptide to be added in bone cements. Other sequences might 
have been more effective. This study however can be used as a good example and 
reference to conduct further work in this area.   
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CHAPTER1: INTRODUCTION AND LITERATURE REVIEW 
 
 
1.1 Bone cements and fillers 
Today trauma and increased life expectancy result in an increase of bone loss 
contributing to a significant raise of the artificial bone market [1]. On the one hand, 
bone defects have usually irregular shape and the gap between the damaged sites is 
often very narrow. On the other hand, minimally invasive surgical techniques are now 
required in orthopaedic surgery in order to avoid infection. Therefore injectable bone 
cements have attracted a lot of attention. There are two main types of bone cements 
used today; acrylic bone cements(ABCs) and calcium phosphate cements(CPCs) [2]. 
Poly (methyl methacrylate) (PMMA) bone cement is one of the most successful 
ABCs developed by Charnley in the 1960s and has played an important role in bone 
cements for many years [3]. ABCs are prepared by mixing a liquid phase and a 
powder phase which form a solid through a polymerization reaction [2]. Although 
they have been widely used, ABCs have many drawbacks. One of them is the 
exothermic polymerization temperature which ranges from 40 to 110⁰C leading to 
bone necrosis. Also, the exothermic polymerisation reaction makes incorporation of 
temperature sensitive drugs such as antibiotics very difficult [4]. Another 
disadvantage is the possibility of un-reacted monomer to be released in the bone 
before polymerisation starts leading to chemical necrosis of bone. The biggest 
problem of ABCs is that they can contribute to implant aseptic loosening which may 
lead to the lack of secondary fixation as well as mechanical failure of bone cements 
[5]. Thus, there was a need for the development of other types of bone cements. In 
1982, LeGeros et al introduced the concept of CPCs [6] and later Brown and Chow 
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obtained the first patent on self-setting CPCs in 1986 [7-9]. Since 1996, the Food and 
Drug Administration approved CPCs to be used for the repair of human cranial 
defects [8]. They can be used for bone repair as substitutes or regeneration materials 
in areas such as the treatment of fracture defects, dental and orthopaedic surgery, 
craniofacial or maxillofacial reconstruction, surface biomaterials for artificial joints, 
etc. They can also be used as drug delivery systems [10-14]. Several significant 
advantages of CPCs have been recognised: 
(1)CPCs are injectable. Although this is a common feature with ABCs, it is an 
important breakthrough in the area of bioceramics. The excellent mould ability, that 
CPCs exhibit results in a perfect fit of cements around the shape of the bone cavity 
and implant. This represents an optimum tissue-biomaterial contact leading to 
decreased possibilities for invasive surgery and can result in bone ingrowth 
stimulation [15]. In this case, CPCs and ABCs are called bone cements, but the 
properties, the chemical nature, and applications are very different, where the CPCs 
show their own superiority. The differences are summarized in Table 1.1 [2]. 
(2)The most outstanding feature of CPCs is their biocompatibility (ISO 10993) and 
bioactivity. The biocompatibility and bioactivity can allow the CPCs to perform the 
requested function in the host and do not induce any unacceptable harm in the 
beneficiary of the medical therapy. At the same time, the tissue of the implant 
recipient forms a direct bond with the material [16,17]. In this case, the CPCs also 
show osteo-conductivity offering a good substrate for osteo-genesis [3, 14,18]. Some 
authors reported that CPCs such as tricalcium phosphate and rhenanite (CaNaPO4), 
are osteotransductive. Osteotransductive is a term, used to describe the in vivo 
behaviour of materials such as the above mentioned, that upon implantation they 
show fast osteointegration but later they are resorbed and slowly replaced by new 
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bone without leaving any gap between material and bone and without losing 
mechanical integrity [19]. 
(3)CPCs can set at body or room temperature and therefore their use cannot lead to 
bone necrosis by hyperthermia. For this reason, the setting reaction offers good 
conditions for many types of drugs or biological molecules to be incorporated. 
Nowadays, CPCs attract a lot of attention in the area of drug delivery [10]. 
(4)The CPC's setting reaction through the dissolution and precipitation process which 
can avoid the drawbacks of a polymerisation reaction as in the case of ABCs the 
polymerisation of which can lead to the release of toxic polymerisation by-
products[15]. 
Table 1.1: Comparison of acrylic bone cements versus calcium phosphate bone cements [2] 
 
Calcium phosphate bone 
cements 
Acrylic bone cements 
Material Ceramic Polymer 
Liquid phase Water or aqueous solutions 
Methyl methacrylate 
monomer 
Powder component Calcium phosphate 
Three basic ingredients: 
PMMA (89wt%),Benzoyl 
peroxide(0.75wt%) & 
Barium sulphate or 
zirconium dioxide (10wt%) 
Setting reaction 
mechanism 
Dissolution-precipitation reaction Polymerization 
Reaction products Brushite or  Hydroxyapatite 
Poly-methyl-methacrylate 
(PMMA) 
Exothermic 
temperature during 
setting 
No-exothermic Exothermic 40-110 ⁰C 
Bioactivity Bioactive Inert 
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1.2 Chemistry of calcium phosphate cements 
CPCs can be produced by the mixture of a powder (that may also contain fillers) with 
water or an aqueous solution containing binders; A paste can be produced by mixing 
the water and the powder which sets at body or room temperature. During the setting 
reaction, one or more calcium phosphate crystals form as nuclei and the precipitate 
sets around the entanglement of the crystal nuclei [3]. The setting process involves 3 
stages [20]:  
(1) Dissolution: the powder dissolves in the liquid phase until saturation of the liquid 
with calcium and phosphate ions. 
(2) Nucleation: the concentration of the reactant ions arrives at a critical peak in the 
liquid phase and leads to the formation of crystallisation nuclei.  
(3) Crystallisation: crystals of the new phase grow in this plastic paste and the system 
begins to harden [20]. 
The process is shown in Figure 1.1. Depending on the setting reaction conditions, 
there is a possibility of the formation of two products: brushite (DCPD) and 
precipitated hydroxyapatite (HA). 
 
 
  
 
 
 
 
Figure 1.1: The process of CPC’s setting reaction 
Powder Liquid 
Plastic paste 
Rigid paste 
Set cements 
Dissolution 
Precipitation 
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1.2.1 Brushite 
Brushite is known as dicalcium phosphate dihydrate (CaHPO4·2H2O) and is formed 
via an acid setting reaction. It is more stable when the pH ranges between 2 and 
4.2[10]. There are two main ways to form brushite [21,22]. 
1. β-Ca3(PO4)2+ Ca(H2PO4)2·2H2O +H2O                         4CaHPO4·2H2O 
2. β-Ca3(PO4)2+ H3PO4+6H2O               3CaHPO4·2H2O 
The brushite cements are resorbable compared to hydroxyapatite (HA) and their 
mechanical strength is lower than HA [23]. Furthermore, DCPD also tends to 
transform into HA after implanted in the body [24]. 
1.2.2 Hydroxyapatite 
The chemical composition of HA [Ca10(PO4)6(OH)2] is close to the mineral 
component of human bones which have the apatitic structure [25]. The apatite 
formula can be presented as Ca10-x(HPO4)x(PO4)6-x(OH)2-x, where x=0-2. The 
stoichiometric HA has x=0 whereas the calcium-deficient hydroxyapatite has 
x=1[26]. The big difference in order to distinguish HA from brushite is that apatite is 
most stable at pH above 4.2 [10]. There are several ways to form HA as 
follows[27,28] 
1. 7Ca4(PO4)2O +2Ca(H2PO4)2
.
H2O         3Ca10(PO4)6(OH)2+3H2O 
2. 3Ca4(PO4)2O +3H2O          3Ca10(PO4)6(OH)2+ 2Ca(OH)2 
3. 2Ca4(PO4)2O + 2CaHPO4
.
2H2O           Ca10(PO4)6(OH)2 +4H2O     
4. 2β-Ca3(PO4)2 + 2CaHPO4 + 2CaCO3         Ca10(PO4)6(OH)2 +2CO2 
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All the above methods could result in HA cement. But considering the experimental 
conditions, method 4 is the easiest way to synthesise hydroxyapatite in the lab. 
Although HA cements exhibit all the advantages of CPCs such as excellent 
mouldability, biocompatibility, bioactivity, osteoconductivity, non-exothermic setting 
reaction and better mechanical properties compared to brushite, HA cements have one 
drawback; the porous structure of HA cements can absorb bacteria which can cause 
potential infections [29]. 
1.3 Bone infections 
A patient can be infected not only due to HA cements that can absorb bacteria, but 
also due to the surgical site and procedure. Some data show that worldwide, the 
number of hip replacements can reach approximately 1 million per annum [30]. Based 
on the large amount of patients with orthopedic implants, the risk of infection is only 
0.5-5% for joint infections but due to the large number of patients infections remain a 
big problem [30, 31]. In order to solve this problem, the use of drugs and antibiotics 
incorporated in CPCs has been studied [10, 40-47, 59-61]. 
The most common bacteria that lead to infections during an operation are Gram-
positive and Gram-negative bacteria [32-35]. In the report from the Public Health 
Laboratory Service Communicable Disease Control Centre, 41.2% of the joint 
infections were caused by Gram-positive bacteria and most of them were caused by 
Staphylococcus aureus (S.aureus); 21.8% were caused by Gram-negative bacteria 
such as Escherichia coli (E. coli) and Pseudomonas aeruginosa (P.aeruginosa) [36]. 
For this reason, S.aureus, P.aeruginosa and E.coli are good candidates in order to test 
the antibacterial capacity of one material or drug. 
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1.4CPCs as drug delivery systems 
CPCs exhibit two characteristics --low exothermal setting reaction and a self-setting 
in vivo ability. Both of these two characteristics are advantageous for antibiotics or 
other temperature sensitive molecules to be incorporated in CPCs [37]. On the other 
hand, biologically active molecules may change some properties of CPCs. Generally, 
the physico-chemical properties (e.g. setting time, porosity, pH & mechanical 
properties) and release kinetics of CPCs have been studied extensively [15]. 
1.4.1Physico-chemical properties of CPCs incorporating low molecular weight 
drugs(LMW) 
Compared to calcium phosphate ceramics when acting as drug delivery systems, 
CPCs cannot only adsorb the drug molecules on their surface but also they can 
incorporate drug molecules throughout the whole volume of the cements by blending 
for example an antibiotic solid in the powder phase or dissolving them in the liquid 
phase [29, 38, 39]. When the LMW drug dissolves in the water phase, the drug 
molecule will be homogeneously distributed within the cement when mixing the 
liquid phase with the powder phase [10]. 
Generally, the incorporation of LMW drugs can increase the setting time and porosity 
of apatite CPCs and if the LMW drug is mixed with the liquid phase, the setting 
reaction will be longer than if the drug was mixed with the solid phase. Moreover, 
increasing the concentration of LMW drug could also increase the setting time and the 
porosity [40,41]. The increase in the setting time may be due to LMW drug chelating 
Ca
2+
 ions instead of phosphate ions reacting with calcium ions [10,42,43] 
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The mechanical properties of antibiotic loaded-CPCs have the opposite tendency with 
setting time. It is believed that addition of antibiotics always decrease the mechanical 
properties of the cements [44]. Furthermore, an increase in porosity or inhibition of 
the setting reaction may contribute to the decrease of mechanical properties [38]. 
During the setting, pH changes may result to partial denaturation of the antibiotic 
activity. Generally, no significant changes have been observed. However, some 
authors reported that pH changes during the setting reaction may result in the loss of 
bactericidal behaviour of antibiotics [45].  
1.4.2LMW release kinetics from CPCs 
The distribution of the drug in the CPCs determines the kinetics of drug release. 
When the drugs are incorporated with the powder phase, the paste tends to precipitate 
a new mineral phase. When the drugs are incorporated with the liquid phase on the 
other hand, a small amount of drugs may interfere with the crystallisation. The drugs 
will remain blocked between the entangled crystals in one of the three ways shown in 
Figure1.2 [10]. 
 
Figure 1.2: Drug in CPCs’ matrix; a) together with the liquid phase which is present in the 
pores between crystal, b) present or bonded with the surface of the new mineral phase, or c) in 
the form of a solid if the amount added is not all dissolved in the liquid phase [10]. 
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Generally, the LMW drugs do not have any effect on the phase formed during the 
setting reaction. The setting reaction is governed by diffusion throughout the CPCs’ 
pores. In the first 24 hours, a burst release of the LMW drug from the CPCs occurs 
[39,46,47] and the LMW drug incorporated in the liquid phase will have higher 
elution efficiency than the ones incorporated in the solid phase [41]. 
Nowadays, the most popular biological molecules in the drug delivery systems are 
antibiotics such as gentamicin, vancomycin, ciprofloxacin or doxycycline [10]. Many 
researchers have applied these antibiotics in CPC delivery systems and received some 
excellent antibacterial bone cements. But their bacterial resistance can still be a 
problem. If the release rate of antibiotics from CPCs is not fast enough to reach the 
minimum inhibitory concentration (MIC) of the antibiotic this can contribute to 
bacterial resistance [15,48,49]. To avoid bacterial resistance, antimicrobial peptides 
have attracted a lot of attention. 
1.5 Antibacterial peptides 
Antimicrobial peptides (APs) are low molecular weight natural compounds composed 
of no more than 50 amino acids [50-52]. APs act as the first line of defence against 
bacterial invasion in almost all forms of life [53]. APs kill bacteria very fast and have 
a broad spectrum of antibacterial activity. Moreover, they are cytotoxic against fungi, 
protozoa, cancer cells, and even viruses [51,54-57]. 
The structure of APs consists of the primary structure, the secondary structure and the 
tertiary structure. The primary structure is the peptide sequence formed by the 
reaction of amino acids from the N-terminus (amine) to C-terminus (carboxylic 
acid)forming a peptide bond (HN-C=O).  
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The secondary structure is the three-dimensional structure of APs and it is classified 
into four families: alpha, beta, combined alpha-beta and non-alpha-beta (see Figure 
1.3) [93]. The alpha family consists of AMPs with helical structures. The beta family 
is composed of AMPs with beta-strands. While the alpha-beta family comprises of 
both helical and beta-strands in the 3D structure, the non-alpha-beta family contains 
neither helical nor β-strands [93]. The diversity of APs discovered is too great to sort 
them except categorize them by the second structure [51]. Until February 2015, the 
Antimicrobial Peptide Database [94-95] (http://aps.unmc.edu/AP/main.php) contained 
2497 antimicrobial peptides. Table 1.2 presents the repartition of these 2497 APs 
among the different classes. 
 
Figure 1.3:3D model structures of the four classes of peptides. (a) alpha peptide (b) beta 
peptide (c) combined alpha-beta peptide (d) non-alpha-beta peptide [93] 
Table 1.2: Repartition of these 2497antimicrobial peptides among the different structural 
classes obtained from the Antimicrobial Database. 
Secondary Structure APs Number  % of total 
α-Helix 349 14 
β-Strands  101  4 
Combinedα- and β-structure 93  4 
Neither α- nor β-structure 470 19 
Unknown 3D structure:  1467  59 
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The tertiary structure is the hydrophilic and hydrophobic properties of amino acids on 
the peptide, which could induce interaction with membranes. The side-chain can 
make an amino acid hydrophilic if the side-chain is polar or hydrophobic if the side 
chain is non-polar. Therefore, as shown in Figure 1.4, if the side amino acid of the 
chain is hydrophilic, peptides will point out to the polar environment and point in to 
the non-polar environment. On the other hand, the hydrophobic side chain will point 
in to the polar environment and point to the non-polar environment. Based on the 
different reaction mechanism, some researchers suggested that the different 
hydrophobic or hydrophilic amino acids on the side peptide chain should affect the 
antimicrobial activity of the peptides [58]. 
 
 
Figure 1.4: The relationship between environment and hydrophilic and hydrophobic amino 
acid. 
 
Based on the Antimicrobial Peptide Database, there are 2497 antimicrobial peptides 
that have been discovered, 2061 of which have an antibacterial activity. They were 
found from different sources like frog, human, sheep, bacteria and etc. [53]. The most 
APs present a broad activity spectrum and against the S.aureus, P.aeruginosa and 
E.coli [51]. Two of them already have been used in bone cements to prevent infection 
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and their sequence is shown in Table 1.3 [59-61, 71, 81]. Stallmann et al [59-61, 71] 
combined both hLF1-11 and DHVAR-5 with several Calcium Phosphate and PMMA 
carriers studied in vivo and vitro to prevent the infection [59, 60, 96]. However, their 
impact on the infection was not ideal due to the poor release of hLF1-11 and DHVAR-
5 [59-61, 71, 96]. Human defensins could possibly be an alternative way of tackling 
bone infection.  
 
Table 1.3:Two antibacterial peptide used in bone cements and their sequence [71] 
Peptide  Structure 
DHVAR-5  LLLFLLKKRKKRKY 
hLF1-11  GRRRRSVQWCA 
 
 
1.5.1 Defensins 
Defensins are small proteins extracted from granulocytes which have 30-40 amino 
acid residues and a molecular weight of around 3-4KD [62]. The main characteristic 
of defensins is that they are cysteine-rich and arginine-rich cationic peptides [62,63]. 
The primarily attractive property of defensins is the broad spectrum of antimicrobial 
activities, moreover, they widely exist in all vertebrates, invertebrates and plants 
[62,64,65]. Defensins could be classified as α-defensins and β-defensins which differ 
in the length of the peptide segments between the cysteines and the pairing of the 
cysteines that are connected by disulphide bonds [63,65]. The main mechanism of 
defensins to destroy microorganisms is through permeability of the plasma membrane 
resulting in leakage of cells content [66]. 
So far, 10 kinds of different human defensins have been discovered. Six of them are 
human α-defensins and four of them are human β-defensins [67]. Human α-defensins 
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are rich in arginine and contain 29-35 amino acids with three disulfide bridges 
connecting residues Cys
1
- Cys
6
, Cys
2
- Cys
4
 and Cys
3
- Cys
5
. Human β-defensins 
contain 35 amino acid and the disulfide bridges which are different from α-defensins 
are Cys
1
- Cys
5
, Cys
2
- Cys
4
, and Cys
3
- Cys
6
. The sequences and disulfide bridges of 
human defensins are shown in Table 1.4 [68-69, 91]. The letter shown in Table 1.4 is 
the abbreviation of amino acid, as shown in ABBREVIATIONS part on the page XIII 
to XVI. 
The main advantage of human defensins is that they were found in  the human body 
and they exhibit a mechanism of resistance which is very old in evolutionary terms. In 
addition, unlike conventional antibiotics such as penicillin, which microbes readily 
circumvent, the defensins could result in minimal induction of bacterial resistance. 
[53, 70-71]. It is shown clearly from Table 1.4 that the sequence of some of the 
defensins is still too long compared to the antimicrobial peptides used in bone 
cements before (Table 1.3) [59,60,71,72]. Recently, there is a lot of interest in 
mimicking the structures of natural defensins and synthetic defensins comprised of 7-
15 amino acids [73]. 
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Table 1.4: The human defensins sequences [68-69, 91]. 
 
1.6 Aims and objectives 
The main aim of this thesis is to isolate short fragments from the antimicrobial core of 
human defensins that can have significant antimicrobial properties and incorporate 
them in CPCs in order to make antimicrobial bone cements.  
Based on the advantages of human defensins mentioned above, α- and β- human 
defensins are the target defensins to be isolated. To select the sequence from human 
defensins, 2 principal elements are taken into account. Firstly, as in cysteine-rich 
cationic peptides mentioned above, the peptide sequence should have at least one 
cysteine. Secondly, for the reason shown before that the hydrophobic or hydrophilic 
amino acid on the side of the chain may bring different antibacterial activity, four 
kinds of different amino acids on the sequence side will be developed; hydrophobic-
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hydrophobic, hydrophilic-hydrophilic, hydrophobic-hydrophilic and hydrophilic-
hydrophobic. Thus, four peptide sequences were selected from α- and β-defensins 
shown in Table 1.5.  
In this study, mass spectrometry and HPLC were used to identify the molar mass and 
purity of peptides. The antibacterial property was studied by measuring the minimum 
inhibitory concentration (MIC) of peptides against S.aureus, P.aeruginosa and E.coli. 
The pH, antibacterial properties, peptide release and mechanical properties 
(compressive strength) of bone cements were measured against different 
concentrations of peptides. 
Table 1.5:Antibacterial peptide sequences studied in this project 
Code Sequence 
AP1 FAM-Ahx-PACIAGERRYG 
AP2 FAM-Ahx-CATRESLSGVC 
AP3 GTCGLPGTKCC 
AP4 FAM-Ahx-CRVRGGRCA 
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CHAPTER 2: MATERIALS AND METHODS 
 
 
2.1 Materials 
All of the materials used in the peptide synthesis were purchased from Sigma-Aldrich 
and Novabiochem, UK. All N-terminals of the amino acids were protected with 
Fluorenyl-methyloxy-carbonyl (Fmoc) groups and the side chain was also protected 
with proper protecting groups. The amino acid and resin beads which were purchased 
from Sigma-Aldrich were: Fmoc-Arg-OH, Fmoc-Tyr-OH, Fmoc-Ser-OH, Fmoc-Val-
OH, Fmoc-Thr-OH, Fmoc-Glu-OH, Fmoc-Ile-OH, Fmoc-Cys-OH as well as the 
solvents and reagents used for SPPS (Solid Peptide Phase Synthesis) and cleavage 
cocktail components: anhydrous dichloromethane (DCM,≥99.8%), anhydrous N,N-
dimethylformide (DMF, ≥99.8%), N,N-diisopropylethylamine (DIPEA, Biotech. 
grade,≥99.5%), Carboxyfluorescein (FAM, BioReagent, HPLC≥95%), piperidine 
(Biotech. grade, HPLC≥99.5%), ninhydrin (Reagent grade), trifluoroacetic acid (TFA, 
HPLC grade, ≥99%) and triisopropylsilane (TIPS,≥99%). The amino acid and amino 
acid preloaded Wang resin beads were obtained from Novabiochem were: Fmoc-Ala-
OH, Fmoc-Ala-Wang, Fmoc-Gly-OH, Fmoc-Gly-Wang, Fmoc-Cys-Wang, Fmoc-
Leu-OH, Fmoc-Lys(Boc)-OH and Fmoc-Pro-OH. The purity of all amino acids was 
above 98%. The anhydrous diethyl ether (Et2O) of HPLC grade for the precipitation 
of peptides was purchased from Fisher Scientific. The Phosphate Buffer Saline (PBS) 
pH=7.4 used for the release studies and dissolving peptides was purchased from 
Sigma-Aldrich. The vessels with cap and fritted disc named Aldrich
®
 system 45
TM
 
which were used in peptide fluorescence labelling and resin cleavage, were purchased 
also from Sigma-Aldrich. 
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The materials used for HA bone cements were Calcium phosphate dibasic (CaHPO4), 
β-tri-calcium phosphate [β-Ca3(PO4)2], Calcium carbonate (CaCO3) and Sodium 
phosphate monobasic dihydrate (NaH2PO4·2H2O). All of them were purchased from 
Sigma-Aldrich and with the purity of over 97%. All of the materials were used as 
received. A Hydrion
®
 Insta-Check
®
 0-13 pH test paper was used for the cement pH 
measurements test and was purchased from Sigma-Aldrich. 
2.2 Antibacterial peptide synthesis 
The peptide synthesis was based on the reaction between the amine group (N- 
terminal) and the carboxylic acid (C-terminal) from two different amino acids to form 
an amide bond which is also known as a peptide bond. Based on the fact that each 
amino acid has both C- and N- terminals, the results of two amino acids reaction 
cannot be controlled in a particular way. In order to solve this problem, Fluorenyl-
methyl-oxycarbonyl (Fmoc) based Solid Peptide Phase Synthesis (SPPS) was used 
here.  [74] 
2.2.1 Peptide synthesized by the Fmoc-SPPS method 
The principle of SPPS is shown in Figure 2.1. All of the amino acids were N-terminal 
protected by a base-labile Fmoc group in SPPS which could be removed by the use of 
piperidine. The C-terminal of the first amino acid as well as all the peptide side chains 
were protected by an acid-labile protecting group, which could be cleaved by 
trifluoroacetic acid (TFA) [74]. This method has the advantage that the Fmoc removal 
mechanism is different from the side chain and the Wang resin beads. [74] Thus, the 
peptide formed should have the desired amino acid sequence. After loading the first 
amino acid, the unprotected N- terminal of the first amino acid reacts with the 
unprotected C-terminal of the second designed amino acid to form a peptide bond. 
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Following this strategy, the peptide sequence assembled from C-terminal to N-
terminal step by step. Before every amino acid was added in, piperidine was added to 
cleave the Fmoc protection groups from the former amino acid. Furthermore, the 
amino acid could not couple automatically at room temperature and therefore O-
(Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU) and 
N,N-Diisopropylethylamine (DIPEA) were used as coupling reagents to form reactive 
intermediates of carboxylic acid assisting the amino acid reaction at ambient 
temperature [75]. 
 
Figure 2.1:Principles of SPPS [74]. 
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In this study, the C-terminal of the first amino acid was protected by Wang resin. All 
amino acids and the Wang resin beads used were already preloaded with the Fmoc-
groups. Peptides were synthesized using a CEM Liberty 1 microwave peptide 
synthesizer using standard SPPS with Fmoc strategy mentioned above. The 
synthesizer was kindly offered by Dr Anna Peacock in the School of Chemistry, 
University of Birmingham. The peptide sequences are shown in Table 1.5. AP1, AP2 
and AP4 were fluorescence labelled at the N-terminal of the peptide sequence with 
carboxyfluorescein (FAM). Considering the bulky FAM may have affected the 
function of the peptide sequence, the 6-Aminocaproic acid (Ahx) was loaded to 
decrease the impact.  
2.2.2 Fluorescence labelling of the peptide sequence 
The final peptide product synthesized by the microwave peptide synthesizer, 
contained the Wang resin, the Fmoc group of the last amino acid and all the side chain 
protecting groups. The first step was to remove the Fmoc groups, then coupling the 
linker (Ahx) and labelling with FAM at the end. 
After taking out the peptide from the synthesizer, the peptides designated by 
fluorescence label were moved into a test tube to be weighed and then transferred to a 
vessel for amine de-protection. Peptides were let to swell in 2mL DMF for 1 hour and 
then reacted with piperidine in a DMF solution (1:5, v:v) for 30 mins to remove the 
Fmoc groups. The reaction solution was shaken by an orbital shaker at 200 rpm. After 
shaking, the solution was vacuum filtered and the remaining solution was discarded. 
The peptide beads were triple washed by DMF (3mL), then, triple washed by DCM 
(3mL) and triple washed by DMF (3mL) again. For the labelling of the peptides the 
following procedure was followed: Fmoc-Ahx-OH (5 eq.) and HBTU (4.9 eq.) were 
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dissolved in DMF (2mL) in a test tube with a vortex mixer for pre-activation. Two 
minutes later, DIPEA (10eq.) was added in the same test tube. Then, the mixture was 
added to the vessel with the peptide for reaction under shaking conditions for 1-2 
hours depending on the results of the Ninhydrin test [92]. Ninhydrin test was applied 
here in order to test whether the peptide coupling was complete. The procedure 
requires that 2mL of aqueous ninhydrin solution (5g/L) was added into a small 
amount of resin beads in a test tube. The test tube was left in boiling water for 3mins 
and then the colour change of the beads was recorded. If there was no colour change 
or the beads colour changed to brown, the coupling was complete. If the colour of 
beads turned to blue, the coupling step was incomplete. After the coupling reaction, 
the beads were vacuum filtered and the remaining solution was discarded. The resin 
beads were washed 3 times × DMF (3mL), 3 times × DCM (3mL) and 3 times × DMF 
(3mL).  
FAM (2 eq.) and DIEPA(16 eq.) were dissolved in DMF (2mL) solution in a test tube 
with a vortex mixer for 10 minutes.[74] This solution was added in the vessel to react 
with the resin beads overnight under shaking conditions at 200 rpm. Considering that 
FAM is sensitive to light, aluminium foil was used to cover the vessel during the 
reaction. The reaction was also tested by the ninhydrin test, the procedure of which 
was described above. After all coupling was completed the resin beads were washed 4 
times in DMF (3mL) and 4 times in DCM (3mL). Then vacuum filtration was used to 
dry the resin beads for 15 minutes. 
2.2.3 Wang resin cleavage and side chains de-protection from the peptide 
As mentioned above, the Wang resin and the amino acid side chain protecting groups 
were all acid-labile by TFA. The procedure is described below: Firstly, the dry resin 
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was weighed and placed in a clean round bottom flask. Then the cleavage cocktail 
made by mixing trifluoroacetic acid (TFA), triisopropylsilane (TIPS) and deionised 
water (95:2.5:2.5, v:v:v) was added to the dry resin in the flask (10mL per 100mg of 
resin) and the mixture was left to be stirred for 2 hours [74]. Aluminium foil was 
wrapped around the flask to prevent the light access. 
2.2.4 Precipitation of peptides 
The round bottom flask used to filtrate the peptide solution, was washed by TFA 
cocktail solution. Then the peptide solution was filtrated and the resin beads were 
removed by filtration. The solution was then left in vacuum for 2-3 minutes for TFA 
to evaporate. The solution was added to ice cold diethyl ether (Et2O) for precipitation 
and the precipitate was left in a freezer at -20°C for 2 hours. The peptide solid was 
then separated from the supernatant by centrifuging at a frequency of 13,500 rpm for 
3 minutes in a test tube and then air dried in a freezer for one night -20 °C. All of the 
synthesized peptides were stored in a freezer at -20 °C. 
2.3 Peptide characterisation 
2.3.1Mass spectrometry 
Electrospray mass spectrometry was used to analyse the peptide sequences. The 
analysis was performed in a Micro mass LCT instrument situated in the mass 
spectrometry facility of the School of Chemistry. 
2.3.2High pressure liquid chromatography 
High pressure liquid chromatography (HPLC) is a technique with which the peptide 
can be identified and purified. With this technique, the solution containing the peptide 
mixture with gradient of solvents (mobile phase) was pumped through a column 
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containing solid adsorbent materials (stationary phase). Each component in the 
peptides can interact with the adsorbent in a different way and therefore the flow rates 
of each component will be different. In this way, the components can be separated at 
different flow times out from the column which will also correspond to a different 
peak in the spectrum. 
HPLC using the analytical Dionex Summit equipment was applied to study the purity 
of the peptides. Preparative HPLC was used for the crude peptide purification. The 
above equipment is located in the School of Chemistry, University of Birmingham. 
During this technique, the stationary phase was the silica bonded by octadecyl carbon 
(C18) chain and the mobile phase consisted of a gradient of solvents, inorganic and 
organic solvents. In this case, the inorganic solvent consisted of water with 0.05% 
TFA and the organic solvent consisted of acetonitrile with 0.05% TFA. UV (λ = 210 
nm) was used to measure eluted molecules, which matches the peptide absorption 
region. 
For the analytical HPLC, each 10 µL of the aqueous peptide solution was injected into 
the column and the column was run for 60 minutes. In these 60 minutes, a linear 
solvent gradient where the 100% was inorganic solvent and 0% organic solvent was 
used. After that, 40% water and 60% acetonitrile were applied. By increasing the 
organic solvent, more hydrophobic molecules were eluted from the column. The 
calculation of purity was based on the integration of peak areas. 
The preparative HPLC follows a similar procedure with the analytical HPLC. 
Different peaks represent different components. In order to purify the peptide, a 
particular component flows out of the column and is collected. Only fluorescence 
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labelled peptides were collected. The collected peptides were identified by mass 
spectrometry. 
2.3.3 Minimum inhibitory concentration (MIC)test of peptides 
2.3.3.1 Preparation of bacteria 
In order to test the antibacterial properties of peptides, bacterial solutions were made. 
S.aureus (NCTC 8532), P.aeruginosa (PA01) and E.coli (MG165S) strains were on 
the agar plate separately. The bacteria were kindly provided by Dr Mark Webber in 
the School of Immunity and Infection. One bacterial bead from the bacterial agar plate 
was taken into a sterile plastic bottle containing 5mL of sterilisation broth. One sterile 
bottle containing 5 mLof sterilisation broth was the control sample. All bottles with 
the different bacteria and the control sample were placed in an oven at 37°C overnight 
under shaking conditions. The next day, if the broth solution in the control bottle was 
clear and the one in the bacteria bottle was cloudy, the bacterial preparation was 
successful and the bacteria culture was ready to use. 
2.3.3.2 MIC test of peptides 
Peptides were dissolved in deionised water. A 96 well cell plate was used in order to 
perform an MIC test. Using a multi-stepper pipette, 50μL of broth were added to the 
wells from the second column to the end. 50μL of peptide solution was added to the 
first and second column. Then using a multi-channel pipette 50μLof double diluted 
peptide solution was added from the second column to the last second one and the 
remaining 50μL of peptide solution were removed and thrown away. The bacteria 
(S.aureus, P.aeruginosa or E.coli) broth culture had to be diluted twice to reach a 
concentration of 10
7 
CFU/mL (1:100). By using a 100μL Gilson pipette, 50μLof 
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diluted organism solution was transferred to the first raw of the well plate ready to 
examine. Finally, a sterile lid was used to cover the plate that was left in the oven for 
18 hours at 37°C. After 18 hours, the MIC was the concentration of the last clear well. 
All peptides were tested three times. 
2.4 Hydroxyapatite bone cements preparation 
The HA cements used in this study was made by mixing the powder and liquid phase 
together. Considering the stoichiometric ratio of HA is Ca/P = 1.67, the powder phase 
consisted of equal moles of dicalcium phosphate anhydrous, calcium carbonate and β-
tricalcium phosphate (β-TCP). All these three powders were mixed together and were 
shaken for 1 hour [28]. The liquid phase was 3 wt% of NaH2PO4·2H2Oin distilled water. 
The ratio of the powder to liquid phase was P/L= 0.4 mL/g. The powder was then 
mixed with the liquid phase in the ratio of 0.4 mL/g for about 1 min and then the 
mixture was poured into PTFE moulds [Figure2.2 (a)] [28]. The mould was covered 
by a stainless steel cover and the mould was fixed into place for 48 hours at 37
o
C with 
the use of a G-clamp device shown in Figure 2.2 (b). 
 
(a)                       (b) 
Figure2.2: (a) HA cements PTFE mould. (b) The HA cements PTFE mould covered by a 
stainless steel cover and fixed with a  G-clamp device. 
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2.5 Characterization of HA bone cements 
2.5.1 X-ray powder diffraction (XRD) 
X-ray Powder Diffraction (XRD) was used in order to identify the phase of HA bone 
cements. Before testing, HA cements were ground into a powder. A Philips X-Pert 
XRD with a continuous scan between 2θ = 10° to90° and a step size of 2θ = 0.02°was 
used. 
2.6 Peptide loading in HA cements. 
Different concentrations of APs2, 6 and 8 wt%, were added in the liquid phase of 
bone cements before mixing. This procedure was performed in a container covered by 
aluminium foil in order to protect the solution from light exposure. The cements were 
then prepared following the steps described in section 2.4. 
2.7 Characterization of antibacterial HA bone cements 
2.7.1 Compressive strength mechanical testing 
The compressive strength (CS) of antibacterial HA bone cements was performed on a 
screw-driven Instron machine (Model 1195, Instron Corporation, High Wycombe, 
UK) filled with a load cell of30kN and using a crosshead speed of 1 mm/min. As 
chematic illustration of the force distribution in the CS testing is shown in Figure 
2.3[76]. All of the cements were packed in a PTFE mould (4 mm × 6mm). After the 
cements setting at 37
o
C as described above, samples were kept in a Phosphate Buffer 
Saline (PBS) for 1 day or 2 days. During the CS study 15 samples of each 
concentration was tested. The compressive strength was calculated by the equation 
below: 
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CS = (4 × P)/(3.14× d
2
) 
where, P represents the maximum force applied at fracture and d represents the 
diameter of the sample cylinder. 
 
Figure 2.3:Schematic representation of the force distribution in the compressive strength 
testing [76]. 
 
2.7.2 In vitro release experiments 
HA cements with 0, 2, 6 and 8wt% of antibacterial peptide were placed (one disc per 
well) in the 24 well cell culture plates and immersed in 1mL of PBS at 37°C. Each 
time 50μL of solution was taken out from each cell after 0.5, 1, 1.5, 2, 2.5, 3, 4, 8, 12, 
24 and 48h. The solution taken out was placed in a 96 well cell plate and analysed 
with a fluorescence micro plate reader. The test excitation wavelength was 485 nm 
and the emission was at 535nm. During the release study three samples of each 
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concentration were tested. The solutions were protected from the light by aluminium 
foil.  
A calibration curve was made in order to calculate the concentration of the release 
solution. A 50μL peptide solution with the concentration already known was tested by 
a fluorescence micro plate reader. The data in the curve was fitted to a straight line. In 
addition, the linear fitting equation is y=13,923,915.86 x. (R
2
=0.98) 
 
Figure 2.4:Calibration curve of peptide concentration. 
2.7.3Antibacterial test of HA cements 
The antibacterial properties of cements and surface of cements were both studied. The 
antibacterial property was measured at two time points, 24 and 48h after setting. The 
method used to test the antibacterial properties was kill kinetics: viable counting using 
the Miles & Misra method [77]. The bacteria used for the antibacterial test were 
prepared as mentioned before in section 2.3.3.1. HA cements with 0, 2, 6 and 8 wt% 
of AP4 were placed one disc per well in the 24 well cell culture plates and immersed 
in 1mL diluted bacterial solution. The 0 wt% of antibacterial peptides was studied as a 
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control sample. A sterile lid was placed on the plate and parafilm was used to cover 
the surface of the plate. Then the plate was placed in the oven for 24h at 37 °C.  
After 24 hours, the broth solution around the sample was diluted for 12 times and 
10μL of the last four dilute solutions were spread on agar plates and these plates were 
placed into an oven overnight at 37 °C. The Colony Forming Unit (CFU) on the plate 
was checked the next day. 
In order to test the bacteria concentration on the surface of the cements, the test 
sample was taken out to be placed into a new 24 well cell plate and the samples were 
immersed in 1mL of PBS. Using 1mL pipette, the bacteria were washed out from the 
surface of the cements into the PBS solution. Then the PBS solution in the well was 
diluted in the same way as the broth solution described above. Ten micro litres of the 
last four dilute solutions were spread on agar plates and these plates were placed into 
an oven overnight at 37 °C. The CFU on the plate was checked the next day. 
2.7.4 pH studies of HA bone Cements 
The pH was measured for all cements just after mixing the solid and liquid phase and 
before the cement pastes were placed into the mould. The pH was measured by a pH 
test paper and compared with the colour chart supplied by the pH paper manufacturer. 
 
Chapter 3                                                                                               Results and Discussion 
 
 
29 
 
CHAPTER 3: RESULTS AND DISCUSSION 
 
 
3.1 Characterisation of solid peptides 
3.1.1 Solid phase peptides synthesis 
The peptides were synthesised by the method of Solid Phase Peptide Synthesis 
(SPPS). The sequence of peptides and the molar mass are presented in Table 3.1 
below. It is worth mentioning, that only AP1, AP2 and AP4 were FITC labelled 
whereas AP3 was not labelled. The reason for this was the antimicrobial activity 
which was believed to be influenced by the FITC labelling. In order to ensure that the 
synthesised peptides had the desired amino acid sequence, mass spectrometry was 
used. In addition, High Pressure Liquid Chromatography (HPLC) was applied in 
order to determine the purity of the synthesized peptides and finally purify the 
peptides. 
 Table 3.1:Peptides sequence and theoretical molar mass of peptides 
Code Peptide sequence Theoretical molar mass (g/mol) 
AP1 (FAM)-Ahx-PACIAGERRYG 1663.85 
AP2 (FAM)-Ahx-CATRESLSGVC 1596.78 
AP3 GTCGLPGTKCC 1039.27 
AP4 (FAM)-Ahx-CRVRGGRCA 1448.6 
 
 
The mass spectrum of AP1 is presented in Figure 3.1. The Y-axis represents the 
relative intensity and the X-axis represents the detected ion molecular weight divided 
by the charge of the ion (m/z). The ionization of the mass spectrum equipment causes 
the molecules to acquire charges by protonating with one or multiple hydrogens (H, 
2H
+
,...nH
+
). Other ions such as sodium adduct or sulphate adduct are also possible. 
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The ion product with different amount of positive charge was detected. The peak 
position represented the detected ion molecular weight divided by the charge of the 
ion. Each peak represents one product. It is also observed that, the peaks of the same 
product but with different isotopic atoms in the molecule result in doublets or triplets 
and the difference between them will be in the range of one neutron. Due to this, the 
charge carried by the ion molecule will be known from the difference between the 
numbers of peaks in the spectrum. For example, if the ion molecule carries 2 charges, 
one neutron divided by the charge 2 will be 0.5, and if the ion molecule carries 3 
charges, one neutron divided by the charge will be 0.33333 and the mass spectrum 
can approximate this value to 0.3. Therefore, from the difference of isotopic atom 
peaks of one product such as 0.3, 0.4 or 0.5, the charge carried by each molecule will 
be known. Based on the above, the molar mass was calculated following the equation 
below:  
Molar weight = A×C - C 
where A= the X-axis value of the peak and C= the charge carried by the molecule. 
The calculated molar mass of AP1 is shown in Table 3.2. From Table 3.2, it can be 
concluded, that the produced peptide product was a mixture of sequences with 
molecular weights of 1029, 1387 and 1745g/mol. The theoretical molar mass of AP1 
was calculated to be 1664 g/mol (Table 3.1). Unfortunately, none of the measured 
molecular weights matched the theoretical value leading to the conclusion that the 
synthesised sequence was not the desired peptide sequence or that the synthesised 
peptide was not pure. 
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Figure 3.1:Mass spectrum of AP1 
 
Table 3.2:Molar mass of AP1 calculated from the mass spectrum 
 Mass/charge Calculated molar mass (g/mol) 
[M+2H]
2+
 515.4 1028.8 
 694.5 1387 
[M+3H]
3+
 463.3 1386.9 
582.7 1745.1 
 
Figure 3.2 shows the HPLC of AP1. Each peak corresponds to one kind of component 
and the relative peak area (Table 3.3) presents the percentage of the component in the 
product. Due to the presence of impurities, there are a few smaller peaks in the HPLC 
spectrum associated with impurities. Therefore, the highest peak was assumed to be 
associated with the main peptide sequence and the area under the highest peak was 
assumed to correspond to the purity of the peptide product. Considering the mass 
spectrum of AP1 (Figure 3.1 and Table 3.2), AP1 did not have high purity and 
required purification by HPLC. 
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Figure 3.2:HPLC spectrum of AP1 
 
Table 3.3:Calculated relative area under each HPLC peaks from the AP1 spectrum 
NO. Time (min) Relative Peak Area (%) 
1 2.72 1.16 
2 16.27 1.52 
3 16.51 48.66 
4 17.05 1.42 
5 17.91 1.33 
6 18.42 1.14 
7 20.73 3.58 
8 20.85 4.62 
9 21.74 4.74 
10 21.93 1.18 
11 25.16 21.78 
12 26.49 0.60 
13 27.66 1.30 
14 31.61 1.46 
15 33.25 4.45 
Total  100.00 
 
The mass spectrometry measurements of AP2 are shown in Figure 3.3 and the 
calculated molar weight is shown in Table 3.4. From Figure 3.3 and Table 3.4, it is 
known that the produced peptide product was a mixture of sequences with molecular 
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weights of 1073, 1120, 1176, 1219, 1431 and 1534.2 g/mol. The theoretical molar 
mass of AP2 was calculated to be 1596.78 g/mol (Table 3.1). The calculated value did 
not match the theoretical molar mass, however, the value of 1534.2 g/mol was the 
closest to the theoretical value.  
Figure 3.3:Mass spectrum of AP2 
 
Table 3.4:Molar mass of AP2 calculated from the mass spectrum 
 Mass/charge Calculated molar mass (g/mol) 
[M+2H]
2+
 537.5 1073 
561.0 1120 
589.0 1176 
610.5 1219 
768.1 1534.2 
716.5 1431 
[M+3H]
3+
 391.3 1170.9 
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The HPLC results of AP2 are presented in Figure 3.4 and the relative percentage of 
each component is shown in Table 3.5. It was observed, that the AP2 had 16 different 
components in the product with the largest amount to correspond to 52.05%. 
Therefore AP2 did not have good purity and it had to be purified.  
 
Figure 3.4:HPLC spectrum of AP2. 
 
Table 3.5:Calculated relative area under each HPLC peak from the AP2 spectrum 
NO. Time (min) Relative Area (%) 
1 2.71 2.45 
2 16.02 1.47 
3 16.35 1.98 
4 16.60 4.91 
5 16.85 2.01 
6 17.16 4.65 
7 17.40 3.87 
8 21.72 12.43 
9 21.92 1.30 
10 23.5 1.36 
11 25.15 52.05 
12 26.49 0.98 
13 27.64 3.12 
14 33.24 5.06 
15 53.42 2.36 
16 53.42 1.06 
Total  100.00 
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Figure 3.5 shows the mass spectrum of AP3 and Table 3.6 presents the observed 
molar mass of AP3 product. From Figure 3.5 and Table 3.6, it can be concluded that 
the observed molar weight were 1039.7 and 1095.8 g/mol. The observed molar weight 
of 1039.7 g/mol was very close to the theoretical molar mass of 1039.27 g/mol shown 
in Table 3.1. 
 
Figure 3.5:Mass spectrum of AP3 
 
Table 3.6:Molar mass of AP3 calculated from the mass spectrum 
 Mass/charge Calculated molar mass (g/mol) 
[M+H]
+
 1039.7 1039.7 
 1096.8 1095.8 
[M+2H]
2+
 520.4 1039.8 
548.4 1095.8 
574.0 1152 
602.5 1203 
 
 
Chapter 3                                                                                               Results and Discussion 
 
 
36 
 
The HPLC spectrum of AP3 is shown in Figure 3.6 and the relative percentage of 
each component is shown in Table 3.7. The AP3 product exhibited 11 different kinds 
of components. However, from the mass spectrum, it can be noticed that AP3 
contained a lot of impurities. Considering that AP3 was not FITC labelled, it could 
not be used in bone cement as there would not be possible study release rates. For this 
reason, AP3 peptide was not purified.  
 
Figure 3.6:HPLC spectrum of AP3 
 
Table 3.7:Calculated relative area under each HPLC peak from the AP3 spectrum  
NO. Time (min) Relative Area (%) 
1 2.72 6.74 
2 13.97 3.19 
3 14.36 2.42 
4 15.88 2.63 
5 21.73 7.06 
6 21.93 11.86 
7 22.77 11.50 
8 25.16 37.03 
9 26.50 3.45 
10 27.67 8.14 
11 53.43 6.00 
Total  100.00 
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The mass spectrum of AP4 is shown in Figure 3.7 and the observed molar mass is 
shown in Table 3.8. From Figure 3.7 and Table 3.8 it can be noticed, that the observed 
molar mass is 1448.2, 1188 and 1807.2 g/mol. The molar mass at 1448.2 g/mol is the 
same as the theoretical mass which is 1448 g/mol (Table 3.1).  
 
Figure 3.7:Mass spectrum of AP4. 
 
Table 3.8:Molar mass of AP4 calculated from the mass spectrum 
 
 Mass/charge Calculated molar mass (g/mol) 
[M+2H]
2+
 725.1 1448.2 
[M+3H]
3+
 397.0 1188 
483.7 1448.1 
603.4 1807.2 
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The HPLC spectrum of AP4 is shown in Figure 3.8 and the relative component 
percentage is shown in Table 3.9. From Figure 3.8 and Table 3.9 it can be observed, 
that there are a lot of impurities in the product. Taking into consideration on the other 
hand the good match between the calculated molar mass and the theoretical molar 
mass as well as the very good MIC test result shown in section 3.1.2, purification of 
the peptide was needed. 
 
 
 
Figure 3.8:HPLC spectrum of AP4 
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Table 3.9:Calculated relative area under each HPLC peak from the AP4 spectrum 
NO. Time (min) Relative Area (%) 
1 2.72 0.44 
2 15.77 0.34 
3 16.80 0.87 
4 17.48 19.66 
5 17.74 29.53 
6 18.31 0.52 
7 18.53 0.18 
8 19.14 0.20 
9 20.89 2.15 
10 21.06 6.72 
11 21.21 8.73 
12 21.50 0.55 
13 21.73 3.51 
14 21.93 0.30 
15 22.78 0.26 
16 23.43 1.02 
17 23.59 1.16 
18 23.73 1.49 
19 24.22 0.27 
20 25.17 13.93 
21 26.50 0.62 
22 27.66 0.49 
23 28.19 0.31 
24 31.62 1.15 
25 31.91 0.18 
26 33.26 4.78 
27 33.85 0.21 
28 53.43 0.43 
Total  100.00 
 
The purification of AP1 was successful. Only one component with fluorescence 
labelling was observed. Then the product was characterised by mass spectrometry and 
HPLC. The mass spectrum of AP1 after purification is shown in Figure 3.9 and the 
calculated molar mass is presented in Table 3.10. The HPLC spectrum is shown in 
Figure 3.10 and the relative percentage of components is presented in Table 3.11. 
From Figure 3.10 it could be easily observed that only one main peak was present 
which reflects to the high purity of the peptide. It is worth mentioning, that the HPLC 
purification was performed only for 40 mins. The peaks above 40 mins corresponded 
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to the solution used to wash the HPLC column. For this reason, the percentage of the 
two peaks NO.8 and NO.9, which have the relative peak area of 0.41 and 63.4, were 
deleted when the purity of AP1 was calculated. The calculated purity of AP1 after 
purification was 84.83%. However, Table 3.10 shows that the observed molar mass is 
1387.5 g/mol which does not match the theoretical molar mass of 1663.85 g/mol 
(Table 3.1) and therefore the sequence of AP1 did not correspond to the initial desired 
sequence. 
 
Figure 3.9:Mass spectrum of AP1 after purification 
 
Table 3.10:Molar mass of AP1 calculated from the mass spectrum after purification 
 Mass/charge Calculated molar mass (g/mol) 
[M+2H]
2+
 694.8 1387.6 
[M+3H]
3+
 463.5 1387.5 
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Figure 3.10: HPLC spectrum of AP1 after purification 
 
Table 3.11: Calculated relative area under each HPLC peak from the AP1 spectrum after 
purification 
NO. Time (min) Relative Area (%) 
1 4.54 0.01 
2 5.73 4.40 
3 9.31 0.75 
4 18.12 0.06 
5 19.34 30.74 
6 19.77 0.17 
7 21.56 0.05 
8 46.45 0.41 
9 56.79 63.40 
Total  100.00 
 
The purification of AP2 peptide was not successful. Fifteen different components 
were observed by fluorescence labelling in the synthesized peptide. This means that 
there was only a tiny amount of the expected peptide sequence and the amount left 
after purification was not enough to conduct any research. The purification of AP4 
was successful. Only one product was observed. The mass spectrum of the purified 
AP4 is shown in Figure 3.11. The calculated molar mass is presented in Table 3.12. 
Chapter 3                                                                                               Results and Discussion 
 
 
42 
 
From Table 3.12, it can be noticed that the observed molar mass of the product was 
1447.8 g/mol and it matched the theoretical molar mass of 1448.6 g/mol (Table 3.1). 
Figure 3.12 shows the HPLC spectrum of AP4 after purification and the relative 
percentage of the components are shown in Table 3.13. The same HPLC method was 
followed for AP4 as for AP1. Thus, the components present after 40mins 
corresponded to the peaks from the solution used to wash the HPLC column. The 
purity of AP4 was 96.55%. The purity of AP4 was sufficiently high to conclude that 
AP4 exhibits the desired amino acid sequence as given in Table 1.5. 
 
Figure 3.11: Mass spectrum of AP4 after purification 
 
Table 3.12:Molar mass of AP4 calculated from the mass spectra after purification 
 Mass/charge Calculated molar mass (g/mol) 
[M+H]
+
 1448.8 1447.8 
[M+2H]
2+
 724.9 1447.8 
[M+3H]
3+
 483.6 1447.8 
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Figure 3.12:HPLC spectrum of AP4 after purification 
 
Table 3.13:Calculated relative area under each HPLC peak from the AP4 spectrum after 
purification 
NO. Time (min) Relative Area (%) 
1 4.66 0.14 
2 9.62 0.30 
3 19.62 96.00 
4 19.94 2.99 
5 56.67 0.57 
Total  100.00 
 
The SPPS method used the Fmoc protection group and the Wang resin gave high 
purity of the sequence. The purity of the peptide decreased as the length of amino acid 
sequence increased due to the theoretical purity of the product being the exponent of 
the purity of each amino acid. Because all purchased amino acids had a purity of 98%, 
the theoretical purity for a 9-amino acid peptide (e.g., AP4) is 0.98
9
 (= 83.37%), for 
an 11-amino acid peptide (e.g., AP1-AP3) is 0.98
11
(=80.07%) and for a 17-amino acid 
peptide is 0.98
17
(=70.93%). Thus, the length of peptides is a very important factor that 
can affect the purity of peptides as shown in Figure 3.13 [78]. The shorter the peptide 
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length, the higher the degree of purity will be. Therefore, the purity of AP4 is 
expected to be higher than AP1, 2 and 3 as it is a shorter amino acid sequence.  
 
Figure 3.13: Relationship between the length and purity of a peptide[78] 
 
3.1.2 The minimum inhibitory concentration (MIC) of synthesized peptide 
MIC was used to identify the antibacterial property of the peptides and the MIC 
results can help to select the peptide with the best antibacterial property to add into 
HA cements. As it was mentioned in section 1.3, E.coli, S.aureus and P.aeruginosa 
are some of the most common bacteria to test the antibacterial ability of the peptides. 
The MIC test was applied in all non-purified peptides. The MIC results of non-
purified peptides are shown in Tables 3.14-3.16. Peptide AP4 showed the lowest MIC 
with a concentration of 5 mg/mL, 2.5 mg/mL and 5 mg/mL for E.coli, S.aureus and 
P.aeruginosa, respectively. The MIC values of peptide AP4 were lower than the MIC 
of AP1, AP2 and AP3. It can be concluded, that AP4 had the best antibacterial 
property. Furthermore, considering the purification results of synthesized peptides, 
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AP4 was the only one that was purified satisfactorily. Thus AP4 was the best peptide 
to add into the HA bone cements. 
After purification, the MIC of AP4 was tested against E.coli, S.aureus and 
P.aeruginosa, and the results are presented in Table 3.17. From Table 3.17, it could 
be seen that the MIC of AP4 against E.coli, S.aureus and P.aeruginosa is 1 mg/mL, 
1mg/mL and 2mg/mL, respectively. These values were lower than the MIC before 
purification showing clearly that the antibacterial property of AP4 was improved after 
purification. 
Table 3.14:MIC values of peptides against E.coli before purification 
Code MIC (mg/mL) 
AP1 10 
AP2 10 
AP3 10 
AP4 5 
 
Table 3.15:MIC values of peptides against S.aureus before purification 
Code MIC (mg/mL) 
AP1 10 
AP 2 10 
AP 3 5 
AP 4 2.5 
 
Table 3.16:MIC values of peptides against P.aeruginosa before purification 
Code MIC (mg/mL) 
AP1 10 
AP 2 10 
AP 3 5 
AP 4 5 
 
 
Table 3.17:MIC values of AP4 against E.coli, S.aureus and P.aeruginosa after purification 
Bacteria MIC (mg/mL) 
E. coli 1 
S. aureus 1 
P. aeruginosa 2 
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3.2 Characterisation of hydroxyapatite bone cements 
3.2.1 X-ray powder diffraction (XRD) studies of hydroxyapatite bone cements 
X-ray powder diffraction was used to characterise the HA cements. Figure 3.14 shows 
the X-ray powder diffraction pattern of HA cements produced during this study. It 
was observed that the cement was crystallized mainly to the phase of hydroxyapatite 
[Ca10(PO4)6(OH)2] and calcium-deficient hydroxyapatite [CaHPO4(PO4)5OH]. A 
minor phase was calcium carbonate (CaCO3) which could have been remained 
unreacted during the HA cement formation. However, as shown in Figure 3.14, the 
main phases in the cement were hydroxyapatite and calcium-deficient hydroxyapatite.  
Comparing the XRD pattern of HA cement (Figure 3.14) with the XRD of HA 
cements reported by Charriere et al (Figure 3.15) [79], both of the HA cements have 
peaks around 2θ=32°and 2θ=26°, which were identified to be associated with HA 
diffraction pattern. In addition, comparing the XRD pattern of HA cement (Figure 
3.14) with the XRD of hydroxyapatite reported by Arsad and Lee [Figure 3.16 
(a)][80]. The diffractogram of the HA cement was similar to the hydroxyapatite phase 
reported in the literature. Both had the strongest peaks around 2θ=32° and the second 
strong peaks around 2θ=26° and 2θ=50°. In addition, the HA cement sample obtained 
in this study also had a similar pattern as the HA standard data in the literature [Figure 
3.16 (b)] [80]. 
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Figure 3.14: X-ray powder diffraction pattern of HA cement sample 
 
 
 
Figure 3.15: X-ray diffraction pattern of HA cements as reported by literature [79] 
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Figure 3.16: X-ray powder diffraction pattern of (a) HA sample in literature and (b) library 
standard of hydroxyapatite as reported in the literature [80] 
 
3.2.2pH studies of hydroxyapatite bone cements 
The pH during hydroxyapatite formation was measured. As mentioned in section 
1.2.2, HA phase is crystallised at pH>4.2 [10]. The pH during HA cement formation 
was 7, which is in the range of HA phase formation. Therefore the phase that is 
expected to be formed during cement formation is hydroxyapatite.  
3.3 Characterization of antibacterial HA bone cements 
Based on the purification results and the MIC test results of antibacterial peptides, 
AP4 was selected to add into the HA cements with the concentration of 0, 2, 6 and 
8wt% and the samples were named AB0, AB2, AB6 and AB8, respectively. The AB0 
was the control sample in all experiments. All the antibacterial HA cements were 
prepared by the method mentioned in section 2.6.  
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3.3.1 pH studies of antibacterial HA cements with peptide 
The pH was measured for all cements just after mixing of the solid and liquid phase 
and before the cement pastes were placed into the mould. The pH was monitored so 
that to monitor the pH change and whether the pH remained > 4.2 in order for HA to 
crystallise (precipitate). If the pH was < 4.2, then brushite would have been 
precipitated instead of HA. In this research all pH values of HA cements with 
different concentration of AP4 were at pH=7. As mentioned in section 1.2.2, the HA 
phase was formed in pH above 4.2 and all the pH value of HA cements in the 
experiment were above 4.2. Even the AP4 had an effect during the HA cements 
setting, but it could not change the main phase of HA. It was concluded that all the 
cement pastes underwent phase transition to HA. 
3.3.2In vitro release study of antibacterial HA bone cements 
The release study was used to analyse the release property of AP4 released from HA 
cements into solution. All the experiments were performed according to the method 
described in section 2.7.2. Figure 3.17 shows the change in the fluorescence intensity 
of the solution (PBS) with time of exposure of cements in PBS. The intensity can be 
correlated directly to the concentration of released peptides into PBS as described in 
section 2.7.2. It can be noticed, that the control sample AB0 showed some 
fluorescence background. AB2, AB6 and AB8 showed an initial burst-release at first 
0.5 hours and a gradual release from 0.5 hours to 3 hours reaching a plateau with no 
significant change up to 48 hours. It is worth noticing, that as the concentration of 
AP4 increased, the fluorescence intensity increased. 
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Figure 3.17:Release profile of AB0, AB2, AB6 and AB8. Error bars represent the standard 
deviation (n= 3) 
 
 
 
Figure 3.18:Concentration of release solution of AB0, AB2, AB6 and AB8. Error bars 
represent the standard deviation (n=3) 
Figure 3.18 shows the change of concentration of AP4 in PBS with time during the 
release studies. It can be noticed, that as the release time increased, the peptide 
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concentration in PBS increased. Similarly with increasing the concentration of AP4 in 
the HA cements, the concentration of peptides in PBS increased. It is also worth 
noticing that, the first 0.5 hour the release speed was higher than between 0.5 hour 
and 3 hours. After 48 hours, the peptide release concentration reached a plateau with 
no significant change. The peptide concentration at 48 hours of AB2 released in PBS 
was 0.195 mg/mL, whereas the concentration of AB6 was 0.23 mg/mL and the 
concentration of AB8 was 0.257 mg/mL. From the peptide concentration and volume 
of PBS, the mass of the released AP4 can be calculated. The mass of AP4 released 
from AB2 was 0.178 mg whereas the mass of AP4 released from AB6 was 0.218 mg 
and the mass of AP4 released from AB8 was 0.240 mg. 
AB2 cement contained 0.83 mg of AP4 whereas AB6 contained 2.5 mg of AP4 and 
AB8 contained 3.33 mg of AP4. Comparing these with the amount of AP4 released 
from the cements, it can be noticed that the mass of AP4 released out was very small. 
Similar results were reported by Stallmann et al. [59,81]. The antibacterial peptide 
hLF1-11(GRRRRSVQWCA) was loaded in 6 different types of commercial 
hydroxyapatite cements in order to study the release property of hLF1-11. A release 
of small amount of peptides was observed for all loaded cements. One of the main 
reasons for this behaviour is that parts of hLF1-11 were strongly bound to the 
hardening cement leading to sequestration and unavailability for release [81]. It is 
worth noticing that some of the amino acids in AP4 (CRVRGGRCA) and hLF1-11 
are similar. For example, both of them have cysteines, a valine, analanine, glycines 
and arginines, with a positive charge. Based on the above, it could be suggested that 
the release behaviour of AP4 from HA could be affected by the binding between AP4 
and the hardening cements. It is also worth noticing that, during the first 0.5 hour a 
higher release rate was observed compared to the 0.5 to 3 hours release period. Kuhn 
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[82] reported an initial burst-release at first 0.5 hours caused by the peptide on the 
surface of the cements and a gradual release from 0.5 hours to 3 hours caused by the 
release of peptides within the cements. 
3.3.3Mechanical properties of antibacterial HA bone cements 
The compressive strength (CS) was measured in order to study the mechanical 
properties of HA cements containing antibacterial peptides. Compressive strength 
tests were conducted for all four concentrations of antibacterial HA cements after 
being immersed in PBS for 24 and 48 hours at 37°C. The reported data were the 
average values of 15 samples. Figure 3.19 shows the wet compressive strength of the 
cements with different concentration of antimicrobial peptides soaked in PBS for 24 
and 48 hours.  
 
Figure 3.19: Compressive strength of AB0, AB2, AB6 and AB8 for 24 and 48h. Error bars 
represent the standard deviation (n=15) 
 
As shown in Figure 3.19, the CS of AB6 and AB8 were lower than the CS of AB0 
and AB2. The CS of AB2 was some lower but nearly the same with AB0, and the CS 
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of AB8 was little lower than AB6. It is clear, that as the concentration of the 
antibacterial peptide increased, the CS of the cement was decreased. But in the range 
of 2 wt% difference, the CS decrease was not significant.  
The setting reaction of cements follows three phases: powder phase dissolution; 
precipitation and crystallisation. Ratieret al [44], reported that the compressive 
strength of HA cements loaded with tetracycline hydrochloride was decreased above 
1% w/w loading. One of the main reasons for this behaviour is that the presence of 
chloride ions was strongly influencing the setting reaction and the formation of 
hydroxyapatite. The treatment of tetracycline hydrochloride however with calcium 
sulphate allowed the loading of the antibiotic up to 7%w/w without decreasing the 
mechanical properties of the cement (HA formation was not interrupted). In this work, 
AP4 has three arginines in the sequence, which carry a positive charge. When the 
powder phase dissolved in the liquid phase, the positive ions might affect the 
crystallisation of HA. How this is happening is not clear as there is no evidence from 
the experimental results. However, it is possible that the peptide bound on the 
hardened cement or the crystallisation of HA was delayed. Most papers in the 
literature reported compressive strength values of hydroxyapatite cements after 2 days 
of setting considering the low compressive strength values that normally occur for all 
HA cements before this time. It is clear, that the compressive strength increased with 
setting time [28,40,41]. Kisanuki et al [41] reported that a cement with high content of 
dideoxy-kanamycin B exhibited low compressive strength and long setting time. 
Furthermore, the compressive strength of cements was lowest at the first 3 days and 
highest at the 7th day of setting. Rabiee et al[40], reported a similar observation. 
Firstly, a long setting time and low compressive strength of HA cements was 
observed at high loadings of tetracycline hydrochloride. Secondly, the highest 
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strength was observed after soaking HA cements in SBF for 7 days and the lowest 
strength was observed for 1 day. One of the reasons for this behaviour was the 
crystallization of HA as well as the crystal growth were slower at the beginning and 
faster at a later time. The low compressive strength of HA cements with high peptide 
concentration could contribute to the long setting time and uncompleted 
crystallization of cements. From Figure 3.19, it could be noticed that the compressive 
strength of HA cements at 48 hours was higher than of 24 hours. Considering the 
results reported by Rabiee et al [40] and Kisanuki et al [41], higher compressive 
strength was expected when the antibacterial cements were incubated for a longer 
time. On the other hand, the porosity could be another reason for the decrease of the 
compressive strength of HA cements. Drug release could produce more pores in the 
cements leading to a lower compressive strength of HA. Rabiee et al[40], suggested 
that the drug release increased the porosity of HA cements leading to the decrease in 
the compressive strength. Barralet et al[83] also observed that with the porosity of HA 
cements increasing, the compressive strength was decreased significantly. In this 
research, considering the release results, the high concentration of AP4 lead to great 
amount of peptide released possibly increasing the porosity of the HA cements. 
However, further work is needed to show the effect of antimicrobial release on the 
porosity of the cements and consequently the decrease of compressive strength.  
3.3.4 Antibacterial assays of antibacterial HA cements 
Antibacterial assays were performed in order to study the antibacterial properties of 
cements as described in Materials and Methods in section 2.7.3. The antibacterial 
behaviour of the surface of cements immersed in PBS for 24 and 48 h was studied.  
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Figure 3.20: E.coli CFU numbers in solution of HA cements with different concentration of 
AP4 (AB0, AB2, AB6 and AB8) for 24 and 48h. Error bars represent the standard deviation 
(n= 3) 
 
The antibacterial test results of all HA cements after 24 and 48 hours in solution are 
shown in Figures 3.20 for E.coli. It is worth noticing that AB8 had the strongest 
properties against E.coli and AB2 had little ability to eliminate bacteria. It can be 
concluded that the HA cements with the highest concentration of AP4 can cause 
stronger effect on E.coli. However, none of the surfaces were free of bacteria after 
48h. In addition, it should be noticed that the CFU numbers of all test samples have 
no significant difference between 24 and 48 hours for E.coli. 
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Figure 3.21: E.coli CFU numbers on the surface of HA cements with different concentration 
of AP4 (AB0, AB2, AB6 and AB8) for 24 and 48h. Error bars represent the standard 
deviation (n= 3) 
 
The antibacterial test results of HA cements after 24 hours and 48 hours on surface for 
E.coli are shown in Figures 3.21. It was observed, that the AB8 had the strongest 
properties against E.coli on the surface and AB2 had nearly no ability to eliminate the 
bacteria. HA cements with higher concentration of AP4 had stronger effect on E.coli 
on the cements surface. It also can be observed, that the ability of eliminating bacteria 
was not significant between 24and 48 hours.  
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Figure 3.22:P.aeruginosa CFU numbers in solution of HA cements with different 
concentration of AP4 (AB0, AB2, AB6 and AB8) for 24 and 48h. Error bars represent the 
standard deviation (n= 3) 
 
The antibacterial test results of HA cements after 24 and 48 hours in solution for 
P.aeruginosa are shown in Figures 3.22. It can be observed, that the AB8 had the 
lowest CFU numbers and AB0 had the highest CFU numbers. It is clear, that HA 
cements with higher concentration of AP4 can cause stronger effect on P.aeruginosa. 
However, the effect was not very strong. It also can be observed, that the ability of 
eliminating bacteria was nearly the same for 24 and 48 hours.  
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Figure 3.23:P.aeruginosa CFU numbers on the surface of HA cements with different 
concentration of AP4 (AB0, AB2, AB6 and AB8) for 24 and 48h. Error bars represent the 
standard deviation (n= 3) 
 
The antibacterial test results of HA cements after 24 and 48 hours on surface for 
P.aeruginosa are shown in Figures 3.23. It can be observed, that the AB8 had stronger 
ability against P.aeruginosa than AB2, however, the antibacterial behaviour of them 
were small. This leads to the conclusion that by increasing the concentration of AP4in 
HA cements, the ability to eliminate bacteria from the surface was increased. 
However, the effect was not very strong. And the ability of eliminating bacteria is 
slightly decreased but nearly the same when the time increases from 24 to 48 hours.  
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Figure 3.24:S.aureus CFU numbers in solution of HA cements with different concentration 
of AP4 (AB0, AB2, AB6 and AB8) for 24h and 48h. Error bars represent the standard 
deviation (n= 3) 
 
The antibacterial test results of HA cements after 24 and 48 hours in solution for 
S.aureus are shown in Figures 3.24. It was observed, that AB8 had the lowest CFU 
numbers and AB0 had the highest. It could be concluded, that the HA cements with 
higher concentration of AP4 can cause stronger effect on S.aureus. It also should be 
noticed, that the ability of eliminating bacterial had not significantly changed when 
the time increased from 24 to 48 hours. 
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c  
Figure 3.25:S.aureus CFU numbers on the surface of HA cements with different 
concentration of AP4 (AB0, AB2, AB6 and AB8) for 24h and 48h. Error bars represent the 
standard deviation (n= 3) 
The 24 and 48 hours on surface antibacterial test results of HA cements for S.aureus 
are shown in Figures 3.35 and 3.36. It can be noticed, that AB8 had the strongest 
effect on S.aureus and AB2 had the weakest. It can be concluded, that as the 
concentration of AP4 in HA cements increased, the ability against S.aureus on the 
cements surface increased. And the ability of eliminating bacterial is almost the same 
between the time of 24 and 48 hours. 
For the antibacterial property in solution, all the results shown above have a similar 
tendency. When the concentration of AP4 in HA cements increased, the antibacterial 
ability increased. However, even for AB8, the sample with the highest concentration 
in antimicrobial peptides was not possible to eliminate all the bacteria. One possible 
reason could be that the concentration of AP4 released with time from the cements 
can never reach the MIC of AP4 as calculated in section 3.1.2. The AB2 contained 
0.83 mg AP4 in the cements, also the AB6 contained 2.5 mg AP4 and AB8 contained 
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3.33 mg AP4 in the sample. When the antibacterial test was conducted, all of the 
samples were immersed in 1 mL bacterial broth solution. Except for the AB2 sample, 
both AB6 and AB8 cements contained enough peptide to reach the MIC of AP4. 
However, considering the release results after 48 hours, the peptide concentration at 
48 hours of AB2 cement sample in solution was 0.195 mg/mL, whereas the 
concentration of AB6 was 0.23 mg/mL and the concentration of AB8 was 
0.257mg/mL (Figure 3.18). In addition, the MIC of AP4 against E.coli, S.aureus and 
P.aeruginosa was 1 mg/mL, 1mg/mL and 2mg/mL, respectively. Therefore, even 
when all HA cements contained the antibacterial peptide AP4 and showed a small 
effect against the bacteria, the effect was not strong enough to eliminate completely 
the bacteria from the surface of the samples.  
With the concentration of AP4 increasing, the antibacterial property was increased, as 
a consequence of the increased release of the antibacterial peptide. In the first 0.5 hour, 
the release was faster compared to the release up to 3 hours. No significant changes 
were observed from 3 hours to 48 hours (Figure 3.17). This is the reason why the 
antibacterial ability in the solution was only slightly different between 24 and 48 
hours. 
Based on the amount of AP4 added in the cements, assuming homogeneous 
dispersion, the volume of the cylindrical sample and assuming that the surface 
thickness is ca 1μm, the surface peptide concentration of the sample was calculated. 
The surface concentration of AB2 was 5.523×10
-3 
mg/cm
2 
whereas the surface 
concentration of AB6 was 0.017 mg/cm
2
 and of AB8 was 0.022 mg/cm
2
. Comparing 
the peptide surface concentration of AP4 with the MIC of AP4, it can be noticed that 
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the peptide surface concentration was much lower than the MIC. Perhaps, this is the 
main reason why the surface antibacterial property of the cements was so poor.  
To our knowledge, there are no other studies exploring the antimicrobial properties of 
peptides in bone cements except of Stallmann et al who reported a study of the release 
behaviour of hLF 1-11 in HA cements as well as the antibacterial property against 
S.aureus in vivo [59,81]. Both studies concluded that it was difficult for the peptide to 
be released out of the cement. In this research, the low release rates resulted in an 
inferior antibacterial behaviour. However, the hLF1-11 could prevent infection better 
than AP4 due to its better MIC value (6.25mg/L) compared to that of AP4 (1 
mg/mL)[59]. On the other hand, the hLF1-11 behaviour against both E.coli and 
P.aeruginosa were not reported and therefore it was not possible to compare the 
antibacterial behaviour of AP4 against these bacteria.  In addition, Nibbering et al[84] 
and Hof et al [85] suggested, that the immunomodulation can affect the antibacterial 
peptide behaviour in vivo, which could lead to a lower concentration of peptide 
capable of eliminating microorganisms and bacteria compared to in vitro studies. It 
can be expected that, a different concentration of peptides should be considered 
(lower than the MIC value obtained in the in vitro experiments) for any in vivo 
studies. 
To prevent infection during surgery, different types of antibiotics can be added in 
calcium phosphate bone cements, e.g. tetracycline hydrochloride, gentamicin, 
kanamycin etc.[40, 41, 86]. Some of these antibiotics perform well when added in 
bone cements for two reasons: first, they have shown good release behaviour and 
second only a small concentration is required to eliminate bacteria. Most of the 
antibiotics could release in the range of 25 to 85% [40,47,87-89]. Rabiee et al [40] 
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reported, that 25% tetracycline hydrochloride could be released from HA cements. 
Ethell et al [47] reported, that 40% gentamic in could be released and 30-40% amikac 
in could be released from HA cements. Stallmann et al[87] suggested that the release 
of gentamic in from different commercial cements could vary from 36 to 85%. 
Takano et al [88] also reported, that gentamic in could be released as much as 70% 
from HA cements. The large amount of antibiotics that can be released contribute to 
increase the porosity of the cements [10]. The amount of antibacterial peptide released 
was not possible to reach the amount of antibiotics release maybe because an 
interaction between the peptide and the cement is possible and a large amount of the 
peptides are in fact bound to the hardening cement as mentioned in section 3.3.2. 
Similar observations were made in the case of hLF1-11 added in the HA cements as 
reported by Stallmann et al[81]. If the peptides are not bound perhaps the antibacterial 
behaviour of cements can be enhanced. Another reason for the low performance of the 
antibacterial cements in this project may be caused by the high MIC of AP4. In 
comparison with the MIC values of common antibiotics (in the order of μg/mL) the 
MIC value for AP4 is much higher in the order of mg/mL. If the antimicrobial 
peptides used in the cements could reach the MIC value of hLF1-11(6.25mg/L), a 
better antibacterial property of the cements would be expected. Nevertheless, the use 
of peptides if compared with the use of antibiotics is always more beneficial as the 
use of antibiotics often results in bacterial resistance something that has not been 
observed or discussed in the case of antimicrobial peptides [90]. 
Another point worth mentioning is that the antibacterial property of the cements was 
generally poor. The 8 wt% of peptide was already the highest possible amount of 
peptide that could be added in the cements so that the cements could be mixed 
effectively. In this work, the peptide was added in the liquid phase with the hope that 
Chapter 3                                                                                               Results and Discussion 
 
 
64 
 
the cement could be mixed better to receive homogeneous distribution of the 
antimicrobial peptide in the cements. For every 1g of powder, 0.4 ml of the liquid 
phase was needed. The highest possible amount of peptide was 8 wt% of 1g powder 
mixed with 0.4 ml of the liquid phase. However, 80 mg of the peptide cannot totally 
be dissolved in 0.4 mL of the solution. When 2 wt% of AP4 was dissolved in the 
liquid phase of cements, all the peptide dissolved in the liquid solution very well and 
it was a transparent solution. But when the 8 wt% peptide dissolved in the liquid 
phase, the solution was not clear which meant that not all of the peptide was dissolved 
in the liquid phase resulting in a turbid liquid. This was a problem that was difficult to 
overcome unless the peptide is added in the powder phase. It is possible that a better 
method to mix the cements could have had an impact on the antibacterial properties of 
the resulting HA cements.  
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CHAPTER 4: CONCLUSIONS 
 
 
The main aim of this project was to isolate fragments from the antimicrobial core of 
human defensins that can have significant antimicrobial properties and incorporate 
them in CPCs in order to make antimicrobial bone cements. Mass spectrometry and 
HPLC were used to identify the molar mass and purity of peptide. The antibacterial 
property was tested by measuring the minimum inhibitory concentration (MIC) of 
peptides. The pH, antibacterial properties, peptide release and mechanical properties 
(compressive strength) of bone cements were measured against different 
concentrations of peptides.  
The following conclusions can be drawn from the above work: 
1. All four fragments from the antimicrobial core of human defensins have 
antibacterial activity against all E.coli, S.aureus and P.aeruginosa. The length of the 
peptide could affect the purity and the purity could impact on the antibacterial 
property of the peptides. Peptide AP4 with the shortest sequence (9-amino acid) had 
the best purity and the lowest MIC. AP4 was selected to be added into HA cements. 
2. The pH was monitored so that to monitor the pH change and whether the pH 
remained >4.2 in order for HA to crystallise (precipitate). In this research all pH 
values of HA cements with different concentration of AP4 were at pH=7. Even the 
AP4 had an effect during the setting of the HA cements, but it could not change the 
main phase of HA. It was concluded that all the cement pastes underwent phase 
transition to HA. 
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c3. The release property was influenced by the concentration of AP4 in the cements. 
With the concentration of AP4 increasing, the amount of peptide released was 
increased. For each concentration, during the first 0.5 hour the release rate was higher 
than between 0.5 hour and 3 hours. After 48 hours, the peptide release concentration 
reached a plateau with no significant change. In addition, the amount of released 
peptide was small. Compared to the results from the literature, the main reason for 
that could be the strong link of the peptide with the hardening HA cement. The 
mechanism of binding was not clear. Further research is required. 
4.The compressive strength was measured to study the effect of the peptide presence 
on the mechanical properties of HA cements. Compressive strength was affected by 
the immersion time in PBS and the concentration of AP4. When the concentration of 
AP4 in the cements was increased, the compressive strength was decreased. The 24 
hours compressive strength of each concentration was lower than 48 hours. The 
decrease of compressive strength with the peptide concentration was probably due to 
the positive ions on the peptide that could delay the crystallisation of HA. An increase 
in porosity with the time is also possible due to peptide release. This would affect 
significantly the compressive strength of the cement. There is no experimental 
evidence for the real reason for the decrease of compressive strength with peptide 
concentration and therefore further study is required to answer this question. The 
increased compressive strength at 48h may be caused by a further crystal growth in 
the cement. 
5. The antibacterial properties of HA cements were affected by the concentration of 
AP4. The antibacterial properties of HA cements were increased with the 
concentration of AP4. However, HA cements with highest concentration 8wt% could 
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not eliminate completely the presence of bacteria. Comparing the results with the 
literature, it can be concluded that the inferior performance of the peptides used in this 
study was attributed to the small amount of peptide released with time (lower to the 
MIC value of the peptide) and the values of MIC that was not low enough compared 
to other peptides in the literature. The antibacterial property between 24 hours and 48 
hours was not very different. The release of peptide was faster at the first 0.5 hour (an 
initial burst-release was observed) and a gradual release from 0.5 hours to 3 hours and 
then reaching a plateau with no significant change up to 48 hours. Thus, there is no 
significant difference in antibacterial properties between 24 and 48 hours. The surface 
concentration of peptide was calculated and found that the concentration of peptide on 
the surface was lower than the MIC of AP4. This may be the cause of the poor 
antimicrobial performance of the cements.  
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CHAPTER 5: FUTURE WORK 
 
 
Further investigation should be conducted in order to develop a complete 
understanding of the mechanism of the effect of peptides on the properties of HA 
cements: 
1. In order to understand the peptide effect on the properties of HA cements, 
compressive strength change for example should be studied for longer setting times 
e.g., 15 days. In addition, the porosity of cements should also be studied at the same 
time length as increase in porosity (perhaps due to peptide release) can affect the 
mechanical properties of cements. A systematic study of the concentration of peptides 
in the cements and its effect on the setting of cements should be also conducted.  
2. FITC labelled peptides could be used for the antimicrobial cements in order to 
observe the distribution of peptides in the cements by Fluorescence microscopy.  
3. Considering that the antibacterial property of bone cements is not good enough, a 
wider concentration of the peptide in bone cements can be studied. For the reason that 
the 8 wt% peptide is already hard to dissolve in liquid phase, the higher concentration 
of peptide can be added into the powder phase instead of in liquid phase. 
4. In this research, the release intensity tested was the cumulative intensity of the 
release solution. It can be changed to test the fresh release liquid in every time point, 
separately. This means that the sample will change to a fresh liquid after each time 
point test and the data will be exactly the released intensity between the last time 
point and next. This way more accuracy in the release data is expected. 
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5. Considering that the fluoresce in label may affect the antimicrobial behaviour of 
peptides, the MIC of peptides with and without fluoresce in label should be both 
tested. 
 6. The reason why the antimicrobial properties of the cements were not very good is 
not clear. For this reason, further study with appropriate experiments is required in 
order to establish whether the peptides interact chemically with the HA cement and 
whether this interaction changes the antimicrobial properties of peptides. 
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